Over a recent four-year period, drug makers contributed more than $72 million to hundreds of United Kingdom patient advocacy groups that lobby and facilitate research into new treatments, and the payments often reflected the commercial priorities of companies making the donations, a new study finds.

Yet transparency about the payments is often lacking, the authors found, underscoring concerns that the pharmaceutical industry may be co-opting patient groups, which frequently work with U.K. agencies to ensure medicines are paid for by the government. As an example, the authors pointed to the National Institute for Health and Care Excellence, which runs cost effectiveness appraisals.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy